Evidence map›Paper›PMID 39223453›Full record

ArticleBMC infectious diseases2024

COVID-19 in the Tibet, China, the roof of the world: a comparative analysis of high-altitude residents and newcomers.

Xiaosong Yan, Ying Shan, Qiaoxia Luo, Dongmei Liu, Yanfei Zhang, Qiangrong Zhai, Zhenxing Zhou, Weikai Wang, Ba La, Jingting Yan and 12 more

Abstract readComparative StudyMulticenter Study
In one paragraph

Article in BMC infectious diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Xiaosong Yan *The Third People's Hospital of Tibet Autonomous Region, Nongke Rd Chengguan District, Lhasa, Tibet, CN-850000, China.
Ying Shan *Clinical Research Academy, Peking University Shenzhen Hospital, Futian District, Lianhua Road 1120Guangdong Province, Shenzhen, CN-518036, China. sylvia.shanboo@gmail.com.
Qiaoxia LuoThe Third People's Hospital of Tibet Autonomous Region, Nongke Rd Chengguan District, Lhasa, Tibet, CN-850000, China.
Dongmei LiuGuangdong Provincial Key Laboratory of Human Disease Genomics, Beishan Rd, Yantian District, Shenzhen, CN-518000, Guangdong, China.
Yanfei ZhangThe Third People's Hospital of Tibet Autonomous Region, Nongke Rd Chengguan District, Lhasa, Tibet, CN-850000, China.
Qiangrong ZhaiGuangdong Provincial Key Laboratory of Human Disease Genomics, Beishan Rd, Yantian District, Shenzhen, CN-518000, Guangdong, China.
Zhenxing ZhouThe Third People's Hospital of Tibet Autonomous Region, Nongke Rd Chengguan District, Lhasa, Tibet, CN-850000, China.
Weikai WangGuangdong Provincial Key Laboratory of Human Disease Genomics, Beishan Rd, Yantian District, Shenzhen, CN-518000, Guangdong, China.
Ba LaThe Third People's Hospital of Tibet Autonomous Region, Nongke Rd Chengguan District, Lhasa, Tibet, CN-850000, China.
Jingting YanClinical Research Academy, Peking University Shenzhen Hospital, Futian District, Lianhua Road 1120Guangdong Province, Shenzhen, CN-518036, China.
Xiaoyao ZhuClinical Research Academy, Peking University Shenzhen Hospital, Futian District, Lianhua Road 1120Guangdong Province, Shenzhen, CN-518036, China.
Xinxin WangGuangdong Provincial Key Laboratory of Human Disease Genomics, Beishan Rd, Yantian District, Shenzhen, CN-518000, Guangdong, China.
Langjie ThuenThe Third People's Hospital of Tibet Autonomous Region, Nongke Rd Chengguan District, Lhasa, Tibet, CN-850000, China.
Wei ChenGuangdong Provincial Key Laboratory of Human Disease Genomics, Beishan Rd, Yantian District, Shenzhen, CN-518000, Guangdong, China.
Qian LiThe Third People's Hospital of Tibet Autonomous Region, Nongke Rd Chengguan District, Lhasa, Tibet, CN-850000, China.
Jian ZengGuangdong Provincial Key Laboratory of Human Disease Genomics, Beishan Rd, Yantian District, Shenzhen, CN-518000, Guangdong, China.
Gang TianThe Third People's Hospital of Tibet Autonomous Region, Nongke Rd Chengguan District, Lhasa, Tibet, CN-850000, China.
Xiaoli ChenThe Third People's Hospital of Tibet Autonomous Region, Nongke Rd Chengguan District, Lhasa, Tibet, CN-850000, China.
Qu CiThe Third People's Hospital of Tibet Autonomous Region, Nongke Rd Chengguan District, Lhasa, Tibet, CN-850000, China.
Qidi ZhouKey Laboratory of Emergency and Trauma, Ministry of Education, College of Emergency and Trauma, Hainan Medical University, Haikou , Hainan, 571199, China.
Xin JinGuangdong Provincial Key Laboratory of Human Disease Genomics, Beishan Rd, Yantian District, Shenzhen, CN-518000, Guangdong, China. jinxin@genomics.cn.
Tashi PingcuoThe Third People's Hospital of Tibet Autonomous Region, Nongke Rd Chengguan District, Lhasa, Tibet, CN-850000, China. pingcuosanyiyuan@163.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAfter a 920-day hiatus, COVID-19 resurged in the Tibet Autonomous Region of China in August 2022. This study compares the characteristics of COVID-19 between high-altitude residents and newcomers, as well as between newcomers and lowlanders.

methodsThis multi-center cohort study conducted at the Third People's Hospital of Tibet Autonomous Region and Beijing University Shenzhen Hospital, included 520 high-altitude resident patients, 53 high-altitude newcomer patients, and 265 lowlander patients infected with the Omicron variant. Initially, we documented epidemiological, clinical, and treatment data across varying residency at admission. We compared the severity of COVID-19 and various laboratory indicators, including hemoglobin concentration and SpO2%, over a 14-day period from the date of the first positive nucleic acid test, as well as the differences in treatment methods and disease outcomes between highlanders and high-altitude newcomers. We also compared several characteristics of COVID-19 between high-altitude newcomers and lowlanders. Univariate analysis, multivariable logistic regression, and the generalized linear mixed model were utilized for the analysis.

resultsNo fatalities were observed. The study found no significant differences in COVID-19 severity or in the physiological measures of hemoglobin concentration and SpO

conclusionsHigh-altitude residents and newcomer patients exhibit clinical similarities. However, the clinical characteristics of high-altitude newcomers and lowlander patients differ due to the impact of the high-altitude environment. These results highlight potential considerations for public health strategies in high-altitude regions such as Tibet.

Indexed as

AltitudeCOVID-19SARS-CoV-2AdolescentAdultAgedCohort StudiesFemaleHemoglobinsHumansMaleMiddle AgedTibetYoung AdultHemoglobinsCOVID-19High-altitude residentsNewcomersTibet

Identifiers

PMID39223453
PMCPMC11370051

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.